معرفی
Chi Wang, Ph.D., is Professor of Internal Medicine and Statistics at the University of Kentucky, Associate Director of the Biostatistics & Bioinformatics Shared Resource, and a lead computational scientist within the Markey Cancer Center. With an h-index of 39 and >5,300 citations, he develops cutting-edge survival-analysis and high-dimensional-omics methods that are translated into prostate, breast, lung and neuroblastoma trials.
Education:
- Ph.D. Biostatistics, Johns Hopkins University, 2009
- M.S. Statistics, Peking University, 2003
- B.S. Mathematics, Peking University, 2001
Research Focus: Wang’s group integrates Bayesian statistics, machine-learning and single-cell sequencing to model tumor evolution, drug resistance and biomarker-driven adaptive trials. Major themes include enzalutamide resistance in prostate cancer, PLK1-mediated immune evasion in lung adenocarcinoma, obesity-adipose drivers of breast cancer, and epigenetic reprogramming of tumor-infiltrating lymphocytes.
Recent Article Trends (2023-2025): Fifteen showcased papers reveal a dual trajectory—(1) mechanistic dissection of kinases (PLK1, DDR1, ABL1/2) and metabolic enzymes (FASN, NNMT, HSP47) that orchestrate resistance and metastasis, and (2) probabilistic algorithms for temporal mutation ordering, biomarker evaluation and single-cell deconvolution. Overarching keywords are precision oncology, drug resistance, tumor micro-environment, and computational systems biology.
Funding & Awards: He is PI/co-I on 152 grants (32 active) from NCI, ACS, V Foundation, etc., totaling >$30 M direct costs. Highlights include NCI U01 for predictive biomarkers, American Cancer Society award on collagen lysyl hydroxylase metastasis drivers, and NCI R01s targeting NNMT in triple-negative breast cancer and TIL epigenetic reprogramming in NSCLC.
Student & Team Mentorship: Wang trains a large multi-disciplinary cohort of Ph.D. students, post-docs and clinical fellows who routinely lead first-author papers and are funded on his grants. His lab sits within the Markey Cancer Center’s Molecular & Cellular Oncology program and the Center for Computational Sciences, fostering daily bench-to-bedside collaboration.
